🔴 Telix Pharmaceuticals is trading 4.7% down in pre-market after announcing US$1.65 billion ITM acquisition

Telix Pharmaceuticals is trading 4.7% down now at $12.00 after announcing a strategic agreement to acquire ITM Isotope Technologies Munich for US$1.65 billion.

• The transaction includes 105.8 million new Telix shares, creating potential dilution, and remains subject to shareholder and regulatory approvals.
• The merger aims to expand isotope production, therapeutic radiopharmaceuticals and supply-chain capabilities.
• Broader markets are higher, making company-specific deal terms the likely catalyst.